(SBTX) – Business Wire
-
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxi
-
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
-
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
-
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
-
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
-
Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
-
Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference
-
Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
-
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021
-
Silverback Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
-
Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
-
Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference
-
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressin
-
Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
-
Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
-
Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
-
Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
-
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric
-
Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference
-
Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
-
Silverback Therapeutics Reports First Quarter 2021 Financial Results
-
Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference
-
Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates
-
Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors
-
Silverback Therapeutics to Present at Upcoming Investor Conferences
-
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Silverback Therapeutics Announces Pricing of Initial Public Offering
Back to SBTX Stock Lookup